期刊文献+

23F型肺炎球菌多糖与CRM197蛋白结合物制备及特性研究 被引量:1

Preparation and Characterization of PNPS23F-CRM197 Conjugates
下载PDF
导出
摘要 目的采用改良胺化还原法,白喉无毒突变体CRM197蛋白作为载体,制备23F型肺炎球菌多糖蛋白结合物。方法在还原胺法的基础上,以1,6-己二酰肼(ADH)为分子臂,在碳二亚胺(EDAC)作用下衍化CRM197蛋白,衍化后蛋白再与多糖上的醛基反应,形成共轭结合;采用高效液相色谱技术(HPLC)、免疫扩散等方法分析结合物,并将获得的结合物免疫NIH小鼠,用ELISA方法检测多糖IgG水平。结果 HPLC图谱和免疫扩散检测结果证明了结合物的获得;动物免疫产生了较多糖高的抗23F肺炎多糖抗体,并有免疫记忆发生。结论采用改良还原氨化法可以制备出动物免疫原性良好的23F型多糖蛋白结合物。 Objective To employ the improved reductive animation (RA) method to prepare Pneumococcal polysaccharide (PN23F polysaccharide) conjugate vaccine, using mutant form of diphtheria toxin CRM197 protein as carrier protein. Methods The oxidized PN23F PS was chemically bound to CRM197 via a linker, adipic acid dihydrazide (ADH). The conjugates were confirmed by HPLC and immunodiffusion assays. The immunogenicity of the conjugate was evaluated in NIH mice and the sera were analyzed with indirect ELISA. Results The profile of HPLC and immunodiffusion showed the existence of conjugates ; the result of immunogenicity showed higher level of anti - PN23F antibody than native PN23F and memory responses in mice. Conclusion The conjugates developed with improved reductive animation method can produce effective immunogenicity in mice.
出处 《职业卫生与病伤》 2013年第2期81-83,共3页 Occupational Health and Damage
关键词 23F型肺炎球菌荚膜多糖 白喉无毒突变体CRM197蛋白 结合疫苗 改良胺化还原法 type 23F pneumocoecal polysaecaride mutant form of diphtheria toxin CRM197 conjugate vaecine improved reduetive animation
  • 相关文献

参考文献8

  • 1Moberley S,Holden J,Tatham D,et al. Vaccines for preven-ting pneumococcal infection in adults [ R]. Cochrane DatabaseSyst Rev,2008,23(1):CD000422.
  • 2ButlerJC, Breim - an R F, Campbell JF, et al. Pneumococ-cal polysaccharide vaccine efficay - An evaluation of currentrecommendations [ J ]. JAMA, 1993, 270(15) :1862-1831.
  • 3徐英,董碧蓉.23价肺炎球菌多糖疫苗预防老年人下呼吸道感染的效果考察[J].中国计划免疫,2005,11(4):287-291. 被引量:40
  • 4NiedermanMS, Ahmed QA. Community - aquired pneumo-nia in elderly patients [ J] . Clin Geriatr Med, 2003,19( 1):101.
  • 5Estimates of disease burden and cost - effectiveness. Geneva,World Health Organization ,2008(http://www. who. int/immunization_monitoring/burden/es-timates-burden/en/index. html; accessed October 2008).
  • 6Vidal J, Franci C. Trinitrophenyl - protein conjugates aremore complex than it is currently thought[ J]. Immunol. Meth,1986,86: 155.
  • 7Chu C, Schneerson R, Robbins JB, Rastogi SC. Further stud-ies on the immunogenicity of Haemophilus influenzae type band pneumococcal type 6 A polysaccharide - protein conjugates[J]. Infect Immun, 1983,40( 1):245-256.
  • 8ZhigangJin, Chiayung Chu, John B,et al. Preparation andCharacterization of Group A Meningococcal Capsular Polysac-charide Conjugates and Evaluation of Their Immunogenicity inMice[ J]. Infect Immun, 2003, 5115 - 5120.

二级参考文献16

  • 1CDC.Prevention of pneumococcal disease [J].MMWR,1997,46(RR-8):1-24.
  • 2Niederman MS,Ahmed QA.Community aquired pneumonia in elderly patients[J].Clin Geriatr Med,2003,19(1):101.
  • 3Fedson D,Henrichsen J,Makela PH,et al.WHO recommendations on pneumococcal vaccination:immunization of elderly people with polyvalent pneumococcal vaccine[J ].Infection,1989,17(6):437441.
  • 4Fedson DS,Shapiro ED,LaForce FM,et al.Pneumococcal vaccine after 15 years of use:another view[J].Arch Intern Med,1994,154:2531-2335.
  • 5Leophonte P,Neukirch F.Anti-pneumococcal vaccination:role and indications in the prevention of community acquired infections of the lower respiratory tract[J].Med Mal Infect,2001,31(4):181-194.
  • 6Sethi S,Murphy TF.Bacterial infection in chronic obstructive pulmonary disease in 2000:a state of the art review[J].Clin Microbiol Rev,2001,14(2):336-363.
  • 7Nichol KL,Baken L,Wurenma J,et al.The health and economic benefits associated with pneumococcal vaccination of elderly persons with dhronic lung disease[J].Arch Intern Med,1999,159:2437-2442.
  • 8Jay C,Robert F,John,et al.Pneumococcal polysaccharide vaccine efficacy:An evaluation of current recommendations [J].JAMA,1993,270(15):1826-1831.
  • 9SiskJE,Moskowitz A J,Whang W,et al.Cost-effectiveness of vaccintion against pneumococcal bacteremia among elderly people [J].JAMA,1997,278(16):1333-1339.
  • 10Christenson B,Lundbergh P,Hedlund J,et al.Effects of a large scale intervention with influenza and 23-valent pneumococcal vaccine in adults aged 65 years or older:a prospective study [J].The Lancet,2001,357:1008-1011.

共引文献39

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部